Cargando…

Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer

Background: Elderly patients receiving anticancer drugs may have an increased risk to develop treatment-related toxicities compared to their younger peers. However, a potential pharmacokinetic (PK) basis for this increased risk has not consistently been established yet. Therefore, the objective of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crombag, Marie-Rose B.S., Joerger, Markus, Thürlimann, Beat, Schellens, Jan H.M., Beijnen, Jos H., Huitema, Alwin D.R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728453/ https://www.ncbi.nlm.nih.gov/pubmed/26729170 http://dx.doi.org/10.3390/cancers8010006

Ejemplares similares

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis
por: Jacobs, Bart A.W., et al.
Publicado: (2019)

Long-term platinum retention after treatment with cisplatin and oxaliplatin
por: Brouwers, Elke EM, et al.
Publicado: (2008)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
por: Verheijen, Remy B., et al.
Publicado: (2017)

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
por: Verheijen, Remy B., et al.
Publicado: (2017)

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents
por: Zandvliet, Anthe S., et al.
Publicado: (2009)

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses
por: Keizer, Ron J, et al.
Publicado: (2015)

Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2019)

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial
por: Verheijen, Remy B., et al.
Publicado: (2017)

Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy
por: van Hasselt, J. G. Coen, et al.
Publicado: (2014)

Corrigendum to “Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy”
por: van Hasselt, J. G. Coen, et al.
Publicado: (2015)

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
por: Keizer, Ron J., et al.
Publicado: (2011)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

Fixed Dosing of Monoclonal Antibodies in Oncology
por: Hendrikx, Jeroen J.M.A., et al.
Publicado: (2017)

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2015)

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites
por: Jager, Nynke GL, et al.
Publicado: (2013)

Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review
por: Verrest, Luka, et al.
Publicado: (2021)

Correction to: Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review
por: Verrest, Luka, et al.
Publicado: (2021)

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment
por: van Andel, Lotte, et al.
Publicado: (2018)

Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach
por: Damoiseaux, David, et al.
Publicado: (2023)

Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors
por: Nijenhuis, Cynthia M., et al.
Publicado: (2016)

A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs
por: Molenaar-Kuijsten, Laura, et al.
Publicado: (2021)

Treatment Individualization in Colorectal Cancer
por: van Geel, Robin M. J. M., et al.
Publicado: (2015)

Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS
por: de Jong, Karen A.M., et al.
Publicado: (2021)

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs
por: Kip, Anke E., et al.
Publicado: (2017)

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080
por: Keizer, Ron J., et al.
Publicado: (2010)

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib
por: Boosman, René J., et al.
Publicado: (2022)

The influence of body mass index on the tolerability and effectiveness of full-weight-based paclitaxel chemotherapy in women with early-stage breast cancer
por: Lin, Lishi, et al.
Publicado: (2022)

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
por: Hendrikx, Jeroen J M A, et al.
Publicado: (2020)

Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?
por: Embaby, Alaa, et al.
Publicado: (2022)

Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin
por: van Hasselt, JGC, et al.
Publicado: (2015)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin
por: van Hasselt, JGC, et al.
Publicado: (2015)

Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling
por: Gast, Marie-Christine W, et al.
Publicado: (2008)

Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies
por: Soto, Elena, et al.
Publicado: (2010)

Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial
por: Joerger, M, et al.
Publicado: (2010)

Mass balance and metabolite profiling of (14)C-guadecitabine in patients with advanced cancer
por: Roosendaal, Jeroen, et al.
Publicado: (2019)

Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies
por: van Eijk, Maarten, et al.
Publicado: (2022)

Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment
por: de Vries Schultink, A. H. M., et al.
Publicado: (2016)

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes
por: van Eijk, Maarten, et al.
Publicado: (2019)

A physiologically based pharmacokinetic model for [(68)Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients
por: Siebinga, Hinke, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t4us1s3ii16skpcp0gm5o3as1t